FDA
-
-
-
-
-
-
-
Johnson & Johnson shows positive results for TALVEY-DARZALEX drug combination
-
-
-
-
-
-
-
Johnson & Johnson reports nipocalimab shows stronger response in Sjögren's patients
-
-
-
-
-
-
-
J&J's RYBREVANT plus LAZCLUZE shows 3.5-year survival in lung cancer study
-
-
-
-
-
-
-
CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research
-
-
-
-
-
-
-
Johnson & Johnson reports clinical trial results for robotic surgery system
-
-
-
-
-
-
-
Johnson & Johnson IMAAVY shows sustained disease control for myasthenia gravis
-
-
-
-
-
-
-
Robotics and AI in Drug Manufacturing: May Unlock Efficiency Gains, Long-Term Value
-
326,122 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

